Science Hub
The science behind
the protocol.
Research, mechanisms, and clinical context for the compounds in the Biohackr.Labs range. Written for clients who want to understand what they are using and why it works.
Weight Management & Metabolic
Retatrutide: The First Triple Agonist
Retatrutide is the first compound to activate GLP-1, GIP, and glucagon receptors simultaneously — producing weight loss outcomes that exceed any single or dual agonist compound currently available.
The TRIUMPH Program: Clinical Evidence for Retatrutide
The TRIUMPH program is Eli Lilly's Phase 3 clinical trial series for retatrutide. Multiple trials across diverse patient populations are producing consistent weight loss data significantly above prior GLP-1 class compounds.
GLP-1, GIP, and Glucagon: The Triple Mechanism Explained
Three receptors, three distinct mechanisms, one compound. This article explains what each receptor does, why the combination matters, and how the glucagon pathway makes retatrutide uniquely different from anything that came before it.
Recovery & Tissue Repair
BPC-157 and TB-500: Peptide Tissue Repair Science
BPC-157 and TB-500 are two of the most studied recovery peptides in the biohacking community, with distinct but complementary mechanisms for tissue repair, inflammation management, and angiogenesis.
GHK-Cu: The Copper Peptide for Skin and Tissue Regeneration
GHK-Cu (copper peptide) is one of the best-researched peptides for skin quality and tissue regeneration. Its mechanism involves the upregulation of collagen, elastin, and a broad range of cellular repair genes.
Hormonal & Growth Hormone Support
HGH and the GHRP Stack: Growth Hormone Axis Support
The growth hormone axis can be targeted at multiple points — directly with HGH 191aa, or through secretagogues (CJC-1295, GHRP-6) that stimulate the body's own GH production. Both approaches have distinct profiles and are suited to different protocol goals.
PT-141: Central Nervous System Arousal Mechanism
PT-141 (bremelanotide) is the only arousal compound that acts centrally — on melanocortin receptors in the brain — rather than on peripheral vascular pathways. This makes it distinct from PDE5 inhibitors in mechanism, use case, and the population of non-responders it reaches.